To appraise the clinical and cost effectiveness of brentuximab vedotin within its marketing authorisation for treating relapsed or refractory CD30-positive cutaneous T-cell lymphoma.
Status Proposed
Process STA
ID number 1190

Project Team

Project lead Stephanie Yates

Email enquiries


Key events during the development of the guidance:

Date Update
12 October 2017 Invitation to participate
24 July 2017 - 21 August 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
26 July 2017 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance